Tanespimycin
Tanespimycin
Tanespimycin (pronounced ta-ne-spim-y-cin), also known as 17-AAG or KOS-953, is a derivative of the antibiotic Geldanamycin. It is an experimental drug that is being studied for its potential use in the treatment of cancer.
Etymology
The name "Tanespimycin" is derived from the chemical name 17-Allylamino-17-demethoxygeldanamycin. The abbreviation 17-AAG stands for 17-Allylamino, 17-demethoxy, Geldanamycin. KOS-953 is a code name given by the pharmaceutical company Kosan Biosciences, which was involved in the initial development of the drug.
Mechanism of Action
Tanespimycin belongs to a class of drugs known as Hsp90 inhibitors. Hsp90 (Heat Shock Protein 90) is a chaperone protein that assists in the proper folding of other proteins, including many that are involved in cell growth and division. By inhibiting Hsp90, Tanespimycin disrupts these processes, leading to cell death in cancer cells.
Clinical Trials
Tanespimycin has been tested in several clinical trials for various types of cancer, including breast cancer, multiple myeloma, and leukemia. However, as of now, it has not been approved by the Food and Drug Administration (FDA) for use in patients.
Related Terms
External links
- Medical encyclopedia article on Tanespimycin
- Wikipedia's article - Tanespimycin
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski